- Programme: Horizon 2020; Call: H2020 SC1-BHC-02-2019
- Funding amount: €6 million, of which €250,000 are for Bavaria
- Funding period: 01/2020-12/2023
- Coordinator: Prof. Dr. Fiorella Guadagni, San Raffaele Roma University
- Project number: 848098
- Website: www.revert-project.eu
REVERT - Targeted therapy for patients with advanced colon cancer
According to the Robert Koch Institute's cancer registry, colorectal carcinoma (colon cancer) is the second most common cancer in both women and men. Although the mortality rate has decreased since the early 1990s, the disease is still the second most common cause of cancer-related death in Germany. This is particularly the case if inoperable metastases have already formed.
Some patients respond well to a therapy, others don't. Why?
The EU project REVERT aims to find out why some patients with metastatic colorectal carcinoma (mCRC) respond very well and some respond very poorly to the same therapies. The researchers want to develop an optimal strategy for the treatment of intestinal cancer. REVERT aims to build a decision-making support system based on artificial intelligence (AI) to develop an innovative combinatorial therapy tailored to the individual patient. The system is intended to recommend the most efficient and cost-effective therapeutic measure for each patient based on clinical and biological characteristics.
Evaluation of the impact of the new treatments on patients' chances of survival and quality of life
This calculation system is based on the set-up of the REVERT database (RDB). It receives its data from a large number of clinical databases, standardised biobank samples and ultimately also from the experience of several large hospitals in Europe. This enables REVERT to evaluate the impact of the new treatments on patients' chances of survival and quality of life.
An EU-wide network of specialists from small and medium-sized enterprises (SMEs), research institutions, clinical centres and biobanks
REVERT is thus also creating an EU-wide network of specialists from small and medium-sized enterprises (SMEs), research institutions, clinical centres and biobanks, focusing on research and development in the field of AI for personalised healthcare. The research results of the network are also available to other EU research institutions for future studies.
The consortium is coordinated by Italy and consists of 13 partners from Germany, Italy, Luxembourg, Romania, Sweden and Spain. The Bavarian partner BioVariance GmbH develops innovative AI solutions for precision medicine in the health, pharmaceuticals and biotechnology sectors and contributes its expertise in this area.
- Intensive consultation during the application process
- Strategic advice on dissemination and exploitation, including intellectual property rights (IPR) and data management
- Support in the preparation of the consortium agreement